Trending News

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

According to a CNBC report, the three investors would collectively hold about 45% of TikTok US.

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.

In an interview with CNBC, the Citadel founder predicted only one more rate cut this year.

The company will establish a dedicated research team to integrate quantum computing algorithms into 3D protein modeling, aiming to create new intellectual property.

Earlier this month, the token also made its debut on Gemini’s crypto exchange, along with support for its USD1 stablecoin.

Signatories include former Federal Reserve Chairs Alan Greenspan, Ben Bernanke, Janet Yellen and others.

Total vehicle sales of the company fell 4.1% year-over-year in the second quarter to 338,031 units, dragging revenue by 6% to $6.59 billion.

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Consumer spending was revised sharply higher, with personal consumption expenditures rising at a 2.5% annualized pace.

This launch, ULA’s third batch of Kuiper satellites, brings Amazon’s total in-orbit constellation to 129 satellites.

Continuing claims, an indicator of the size of the total unemployed population, increased by 2,000 to 1.92 million.

Transocean increased its planned share offering from 100 million to 125 million shares at $3.05 per share.

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

The coffee chain announced that its board has approved a restructuring plan that will close select company-operated locations and reduce non-retail headcount under its “Back to Starbucks” turnaround strategy.

Strong fundamentals, low debt, and bullish chart patterns point to a potential reversal, according to the analyst.

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

A U.S. registry of clinical trials shows that the study has been terminated for strategic business reasons.

Heavy selling in technology, auto, and pharma stocks weighed on sentiment.

Analyst said this will benefit scalpers, retail traders, and popular stocks like Zee, IDFC First, and Vodafone Idea.

Since hitting a bottom of $79.75 on April 7 amid the sell-off triggered by Trump tariffs, the stock has added nearly 200%.

Board meeting on September 27 to consider a stock split as well as the issue of bonus shares.

An analyst highlights potential upside if the stock trades above ₹168.50-₹169.

The tablets will be manufactured at Lupin’s Nagpur facility and are indicated for adults and pediatric patients weighing at least 25 kg.

Analyst flags all three as potential multi-week winners driven by technical breakouts and improving fundamentals.

The investment lifts Tata Steel’s cumulative stake in its Singapore-based subsidiary T Steel Holdings to $460 million this year.

The company also secured a ₹21.24 crore order from Kshema General Insurance for its policy administration system.

The company secured ₹3,200 crore in funding support from State Bank of India to back large-scale solar and hybrid projects in Gujarat.

Ethereum led the declines, slipping 0.3% to $4,033.24, according to CoinGecko data, while Bitcoin was down 0.6% at $111,832.

Overall car registrations in the EU rose 5.3% as buyers continued shifting toward electrified vehicles, which made up more than 62% of the market.

BSE’s stellar rally has cooled, with shares sliding 26% over the last three months. An analyst cautions that earnings could dip if derivatives volumes shrink further.

The lender has reported steady profit growth, improved asset quality, and a stronger return on equity, with credit expansion and digital initiatives expected to support momentum into FY26.

SBI Life shares are consolidating near record highs, with analyst Mayank Singh Chandel pointing to strong long-term trends.

Analysts warn that a break below 25,000 could trigger intensified selling. FII outflows and MSCI rebalancing risks may weigh on sentiment.

JLR’s production halt has weighed on Tata Motors, which trades in bearish territory. An investment advisor sees strong resistance near ₹700.

Shares of the Chinese retailing giant were up 6.2% in Hong Kong on Thursday afternoon.

Metals and defence stocks gained, while autos and realty weighed on sentiment.

The trial’s enrollment target has been raised to 339 patients, with completion expected by late 2026.

The focus has shifted to Tesla’s upcoming third-quarter deliveries, with some analysts projecting stronger-than-expected numbers.

Intel’s stock continued to rise as the company actively seeks outside investments to bolster its sagging fortunes.

The stock has already seen a fivefold increase this year, giving it a valuation of over $19 billion, more than three times the market capitalization of rival NuScale Power.

More than 500 lawsuits over Tylenol and autism were dismissed last year, but families are now appealing to the 2nd U.S. Circuit Court of Appeals, which is scheduled to hear arguments on Oct. 6.

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Intel’s stock has gained nearly 56% year-to-date as the company has made concerted efforts under new CEO Lip-Bu Tan to turn around its fortunes.

France’s economy ministry has reportedly scheduled an Oct. 7 inspection of Nissan’s European headquarters after requesting full 2024 accounting and payment records.

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

The analyst’s new target of $26 implies an upside of about 17% from the stock’s closing price on Tuesday.

The SEC filing indicates that the ETF would weight companies based on market capitalization and crypto holdings and allocate up to 15% to PIPEs within liquidity constraints.

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.